Jnk P38 Mapk Signaling In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways are critical stress-activated signaling cascades that play complex roles in neurodegeneration. Originally characterized as responses to cellular stress, these pathways have emerged as key mediators of neuronal death, neuroinflammation, and protein aggregation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. [1]
| Component | Function | Neurodegenerative Relevance | [2]
|-----------|----------|----------------------------| [3]
| MKK4/7 | Upstream MAPKK kinases | Phosphorylates and activates JNK |
| JNK1/2/3 | Stress-activated kinases | JNK3 predominantly in neurons |
| c-Jun | Transcription factor | AP-1 complex component |
| Bim | Pro-apoptotic BH3-only protein | Mitochondrial apoptosis driver |
| ATF2 | Transcription factor | Stress gene expression |
| p53 | Tumor suppressor | DNA damage response |
| Component | Function | Neurodegenerative Relevance |
|---|---|---|
| MKK3/6 | Upstream MAPKK kinases | Selective activation of p38 isoforms |
| p38α | Ubiquitous isoform | Cytokine production |
| p38β | Brain-enriched | Neuronal function |
| p38γ | Muscle/neuronal | Synaptic plasticity |
| p38δ | Kidney/lung | Stress response |
| MK2/3 | Downstream kinases | mRNA stability |
JNK and p38 phosphorylate transcription factors that drive pro-apoptotic gene expression:
p38α in microglia drives:
| Drug/Compound | Stage | Notes |
|---|---|---|
| SP600125 | Research | Anthrapyrazolone, broad JNK inhibition |
| JNK-IN-8 | Research | JNK1/2/3 selective |
| CEP-1347 | Clinical (failed) | Mixed lineage kinase inhibitor |
| D-JNKi | Research | Peptide inhibitor |
| Drug/Compound | Stage | Notes |
|---|---|---|
| SB203580 | Research | p38α/β selective |
| SB239063 | Research | Advanced inhibitor |
| PH-797804 | Clinical | COPD trials |
| Losmapimod | Clinical | Phase 3 for FSHD |
The study of Jnk P38 Mapk Signaling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications highlighting key advances in this mechanism:
Mehan et al. (2019) demonstrated that JNK signaling plays a critical role in the selective vulnerability of dopaminergic neurons in Parkinson's disease ^4. The JNK3 isoform is predominantly expressed in neurons and becomes activated in response to mitochondrial toxins and alpha-synuclein pathology.
Park et al. (2024) showed that p38 MAPK inhibition reduces alpha-synuclein toxicity through improved autophagy and reduced oxidative stress ^5. This finding establishes JNK/p38 as therapeutic targets in synucleinopathies.
Cheng et al. (2023) elucidated the mitochondrial signaling pathways by which JNK promotes neuronal death, including direct phosphorylation of Bcl-2 family proteins and modulation of complex I activity ^6.
Gupta et al. (2023) demonstrated that JNK-mediated tau phosphorylation at multiple sites (Thr181, Ser396, Ser404) accelerates NFT formation ^7. The JNK-tau axis represents a key link between stress signaling and protein pathology.
Tong et al. (2022) reviewed p38 MAPK's role in driving neuroinflammation through microglial activation and cytokine production, establishing a vicious cycle between inflammation and neuronal dysfunction ^8.
Kumar et al. (2022) evaluated p38 MAPK inhibitors in preclinical AD models, showing reduced amyloid deposition and improved cognitive function ^9. However, systemic toxicity remains a challenge.
Schneider et al. (2022) showed that JNK activation precedes motor neuron death in SOD1 mutant mice, and JNK inhibition extends survival through reduced glial activation ^10.
Emerging evidence links TDP-43 proteinopathy to JNK activation, suggesting a common pathway across ALS subtypes.
| Drug | Target | Stage | Indication |
|---|---|---|---|
| CC-930 | JNK1/2 | Phase I | IPF |
| SR-3306 | JNK1/2/3 | Preclinical | PD |
| SP600125 | JNK1/2/3 | Preclinical | AD |
Liu et al. (2024) reviewed crosstalk between JNK/p38 and other pathways, highlighting potential combination strategies with antioxidant therapy, anti-inflammatory agents, and metabolic modulators ^11.
Chen S, Barnstable CJ, Zhang X. A PEDF peptide mimetic effectively relieves dry eye in a diabetic murine model by restoring corneal nerve, barrier, and lacrimal gland function. Ocul Surf. 2024. ↩︎ ↩︎
Mustafa AM, Shaheen AM, Zaki HF. 'Nicorandil and carvedilol mitigates motor deficits in experimental autoimmune encephalomyelitis-induced multiple sclerosis: Role of TLR4/TRAF6/MAPK/NF-κB signalling cascade'. Int Immunopharmacol. 2024. ↩︎ ↩︎
Mehan S. JNK signaling in neurodegenerative diseases. Neuropeptides. 2019. ↩︎
Yu N, Wu X, Zhang C. NADPH and NAC synergistically inhibits chronic ocular hypertension-induced neurodegeneration and neuroinflammation through regulating p38/MAPK pathway and peroxidation. Biomed Pharmacother. 2024. ↩︎